<DOC>
	<DOC>NCT02655614</DOC>
	<brief_summary>This first-in-human, double-blind, placebo-controlled Phase I study will be conducted in participants with amyotrophic lateral sclerosis (ALS) to explore safety, tolerability, and pharmacokinetic (PK) properties of GDC-0134. It will include two components: a Single-Ascending-Dose (SAD) stage and a Multiple-Ascending-Dose (MAD) stage.</brief_summary>
	<brief_title>A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Male or female participants with a diagnosis of possible, laboratorysupported probable, probable, or definite ALS according to modified El Escorial criteria Upright forced vital capacity of at least 60 percent (%) Ability to fast from food for 8 hours prior to dosing and 2 hours after dosing Currently taking riluzole unless on a stable dose for the 3 months prior to screening and without current liver enzyme or liver function abnormalities Positive for hepatitis C antibody, hepatitis B surface antigen, or human immunodeficiency virus (HIV) antibody Clinically significant thrombocytopenia Currently taking nutritional/herbal supplements, except for overthecounter vitamins that are within Recommended Dietary Allowance (RDA), unless discontinued at least 7 days prior to Day âˆ’ 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>